EE04929B1 - Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450 - Google Patents

Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450

Info

Publication number
EE04929B1
EE04929B1 EEP200100406A EEP200100406A EE04929B1 EE 04929 B1 EE04929 B1 EE 04929B1 EE P200100406 A EEP200100406 A EE P200100406A EE P200100406 A EEP200100406 A EE P200100406A EE 04929 B1 EE04929 B1 EE 04929B1
Authority
EE
Estonia
Prior art keywords
methyl
fluorophenyl
pyrimidine
isopropyl
amino
Prior art date
Application number
EEP200100406A
Other languages
English (en)
Estonian (et)
Inventor
induktorit v?i substraati ja sellise koostise kasutamine
Raza Ali
Stuart Pears John
Gerard Hutchinson Howard
Schneck Dennis
Baba Takahiko
Touchi Akira
Yamaguchi Yoshitaka
Original Assignee
Astrazeneca Ab
Shionogi & Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04929(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Application filed by Astrazeneca Ab, Shionogi & Co. Ltd. filed Critical Astrazeneca Ab
Publication of EE200100406A publication Critical patent/EE200100406A/xx
Publication of EE04929B1 publication Critical patent/EE04929B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EEP200100406A 1999-02-06 2000-02-01 Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450 EE04929B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination
PCT/GB2000/000278 WO2000045817A1 (en) 1999-02-06 2000-02-01 Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4

Publications (2)

Publication Number Publication Date
EE200100406A EE200100406A (et) 2002-10-15
EE04929B1 true EE04929B1 (et) 2007-12-17

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100406A EE04929B1 (et) 1999-02-06 2000-02-01 Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450

Country Status (28)

Country Link
US (3) US6982157B1 (pl)
EP (1) EP1185274B1 (pl)
JP (2) JP2002536331A (pl)
KR (2) KR20010101790A (pl)
CN (1) CN1165310C (pl)
AR (1) AR029333A1 (pl)
AT (1) ATE282415T1 (pl)
AU (1) AU767304B2 (pl)
BR (1) BR0007999A (pl)
CA (1) CA2358632C (pl)
CZ (1) CZ301296B6 (pl)
DE (1) DE60015965T2 (pl)
EE (1) EE04929B1 (pl)
EG (1) EG23858A (pl)
ES (1) ES2232418T3 (pl)
GB (1) GB0000710D0 (pl)
ID (1) ID30485A (pl)
IL (1) IL144715A0 (pl)
IS (1) IS2337B (pl)
MX (1) MXPA01007905A (pl)
MY (1) MY130606A (pl)
NO (1) NO320745B1 (pl)
NZ (1) NZ512982A (pl)
PL (1) PL198034B1 (pl)
PT (1) PT1185274E (pl)
TR (1) TR200102228T2 (pl)
TW (1) TWI282738B (pl)
WO (1) WO2000045817A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
CA2540984C (en) 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
WO2007005941A2 (en) 2005-07-05 2007-01-11 President And Fellows Of Harvard College Liver targeted conjugates
WO2007071357A2 (en) 2005-12-20 2007-06-28 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising (e) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5 -yl- (3r, 5s) -3, 5-dihydr0xyhept-6-en0ic acid
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
WO2019241519A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
BR112022001514A2 (pt) * 2019-07-31 2022-03-22 Intas Pharmaceuticals Ltd Composição farmacêutica multicamada e processo para a preparação de uma composição farmacêutica
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
ATE114286T1 (de) * 1991-07-02 1994-12-15 Benckiser Gmbh Joh A Zusammenfaltbare vorratsflasche.
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
EP1027045A4 (en) * 1997-10-31 2004-12-08 Arch Dev Corp METHODS AND COMPILATIONS FOR REGULATING S-ALPHA REDUCTASE ACTIVITY

Also Published As

Publication number Publication date
PT1185274E (pt) 2005-03-31
US20060040969A1 (en) 2006-02-23
WO2000045817A1 (en) 2000-08-10
IL144715A0 (en) 2002-06-30
US20090042911A1 (en) 2009-02-12
CZ301296B6 (cs) 2010-01-06
US6982157B1 (en) 2006-01-03
JP2002536331A (ja) 2002-10-29
ID30485A (id) 2001-12-13
NZ512982A (en) 2003-08-29
NO20013811D0 (no) 2001-08-03
IS2337B (is) 2008-02-15
EP1185274A1 (en) 2002-03-13
TWI282738B (en) 2007-06-21
BR0007999A (pt) 2001-11-06
ATE282415T1 (de) 2004-12-15
DE60015965T2 (de) 2006-01-05
ES2232418T3 (es) 2005-06-01
NO320745B1 (no) 2006-01-23
AU2121800A (en) 2000-08-25
CN1338936A (zh) 2002-03-06
KR20010101790A (ko) 2001-11-14
NO20013811L (no) 2001-10-02
IS6009A (is) 2001-07-17
EG23858A (en) 2007-11-18
AU767304B2 (en) 2003-11-06
EE200100406A (et) 2002-10-15
GB0000710D0 (en) 2000-03-08
PL198034B1 (pl) 2008-05-30
PL364780A1 (pl) 2004-12-13
CN1165310C (zh) 2004-09-08
DE60015965D1 (de) 2004-12-23
KR20060117381A (ko) 2006-11-16
CA2358632C (en) 2008-10-28
MY130606A (en) 2007-07-31
AR029333A1 (es) 2003-06-25
TR200102228T2 (tr) 2002-03-21
CA2358632A1 (en) 2000-08-10
CZ20012844A3 (cs) 2001-11-14
JP2007277267A (ja) 2007-10-25
EP1185274B1 (en) 2004-11-17
MXPA01007905A (es) 2003-06-04
HK1041817A1 (en) 2002-07-26

Similar Documents

Publication Publication Date Title
EE04929B1 (et) Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450
EE05586B1 (et) Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees
HUP0204051A3 (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid, process for their preparation and pharmaceutical compositions containing them
IL155919A (en) (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia
DK1897546T3 (da) Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre
HUP0302980A3 (en) Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moeties as inhibitors of protein junkinases and pharmaceutical compositions containing them
PL352373A1 (en) Noval use of 1-[4-(5-cyanoindol-3-ilo)butyl]-4-(2-carbamoilobenzofuran-5-yl)piperazyne and physiologically tolerated salts thereof
HUP0402092A3 (en) Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions
WO2010030201A3 (en) Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid
HK1040924A1 (zh) 降膽固醇劑的應用
HUP0002459A3 (en) Salts of optically active sulfoxide derivative, pharmaceutical compositions containing them and use thereof
NZ308110A (en) Polymorphs of lesopitron dihydrochloride, ie 2-[4-[4-[4- (chloropyrazole-1-yl)butyl]-1-piperazinyl]pyrimidine, and its hydrated forms, preparation and pharmaceutical compositions
HUP0104977A3 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231